Literature DB >> 28784422

Elevated seroprevalence of Toxoplasma gondii in AIDS/HIV patients: A meta-analysis.

Lei Liu1, Li-Na Liu2, Peng Wang2, Tian-Tian Lv2, Yin-Guang Fan2, Hai-Feng Pan3.   

Abstract

Clinical toxoplasmosis in AIDS/HIV patients is a great public health concern around the world. Untreated Toxoplasma gondii (T. gondii)-infections are often fatal in AIDS/HIV patients. This study aims to assess the seroprevalence and odds ratio (OR) of T. gondii in AIDS/HIV patients, as well as the potential influential factors. Studies published from December 1, 1983 to December 1, 2016 in English, which comparing the seroprevalence of T. gondii between AIDS/HIV patients and control group were searched in PubMed, EMBASE and The Cochrane Library databases. The non-weighted prevalence, pooled fixed-effect or random-effect model estimates of OR and its 95% confidence intervals (CI) were all calculated. Heterogeneity test was performed by the Q statistic and quantified using I2, publication bias was evaluated using a funnel plot and Egger's linear regression test. A total of 4220 articles were obtained after searching databases, and 12 studies with 2101 AIDS/HIV patients and 5851 controls were incorporated in the meta-analysis. Meta-analysis revealed that, compared with the control group, the AIDS/HIV group had a higher seroprevalence of T. gondii (46.12% vs 36.56%) (OR=1.55, 95%CI: 1.19-2.04). Subgroup analyses showed that publication year, race, geographic locations and diagnostic methods are positive associated with the seroprevalence of T. gondii. Overall, our study suggests that AIDS/HIV patients have higher seroprevalence of T. gondii than those without.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIDS; HIV; Meta-analysis; Toxoplasma gondii

Mesh:

Substances:

Year:  2017        PMID: 28784422     DOI: 10.1016/j.actatropica.2017.08.001

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  6 in total

Review 1.  Sixty Years (1957-2017) of Research on Toxoplasmosis in China-An Overview.

Authors:  Ming Pan; Congcong Lyu; Junlong Zhao; Bang Shen
Journal:  Front Microbiol       Date:  2017-09-25       Impact factor: 5.640

2.  Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil.

Authors:  Marcelle Mareze; Aline do Nascimento Benitez; Ana Pérola Drulla Brandão; Fernanda Pinto-Ferreira; Ana Carolina Miura; Felippe Danyel Cardoso Martins; Eloiza Teles Caldart; Alexander Welker Biondo; Roberta Lemos Freire; Regina Mitsuka-Breganó; Italmar Teodorico Navarro
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

3.  The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 Are Crucial Along the Induction of Cerebral Toxoplasmosis.

Authors:  Timothy French; Nicole Israel; Henning Peter Düsedau; Anne Tersteegen; Johannes Steffen; Clemens Cammann; Eylin Topfstedt; Daniela Dieterich; Thomas Schüler; Ulrike Seifert; Ildiko Rita Dunay
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

4.  Analysis of Deaths among HIV-Infected Patients Hospitalized in 2009-2018 in Main Centre of Infectious Disease in Region of Lower Silesia in Poland, Detailing Lesions in the Central Nervous System.

Authors:  Justyna Janocha-Litwin; Aleksander Zińczuk; Sylwia Serafińska; Anna Szymanek-Pasternak; Krzysztof Simon
Journal:  Medicina (Kaunas)       Date:  2022-02-11       Impact factor: 2.430

5.  Seronegative Infection with Toxoplasma gondii in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Patients and in Blood Donors.

Authors:  Agnieszka Pawełczyk; Małgorzata Bednarska; Kamila Caraballo Cortés; Marianna Glamkowska-Sady; Justyna Kowalska; Beata Uszyńska-Kałuża; Marek Radkowski; Renata Welc-Falęciak
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

6.  Misdiagnosis of HIV With Toxoplasmosis Encephalopathy With Progressive Memory Loss as the Initial Symptom: A Case Report.

Authors:  Jingjing Wu; Xiumei Luo; Nanqu Huang; Yuanyuan Li; Yong Luo
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.